Koninklijke Philips N.V. (NYSE:PHG) Stake Trimmed by Mondrian Investment Partners LTD

Key Points

• Mondrian Investment Partners LTD reduced its stake in Koninklijke Philips N.V. by 0.3%, now owning approximately 7.11 million shares, representing 3.1% of its portfolio.
• Koninklijke Philips shares recently traded at $26.98, with a market capitalization of $25.98 billion and a P/E ratio of 142.00.
• Analysts have downgraded Koninklijke Philips from a "buy" to a "hold" rating, with the stock currently receiving a "Moderate Buy" average rating from five analysts.

Mondrian Investment Partners LTD lessened its holdings in Koninklijke Philips N.V. (NYSE:PHG - Free Report) by 0.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,111,484 shares of the technology company's stock after selling 23,582 shares during the period. Koninklijke Philips comprises 3.1% of Mondrian Investment Partners LTD's investment portfolio, making the stock its 7th biggest holding. Mondrian Investment Partners LTD owned 0.76% of Koninklijke Philips worth $180,632,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Colonial Trust Co SC raised its holdings in shares of Koninklijke Philips by 724.0% in the 4th quarter. Colonial Trust Co SC now owns 1,409 shares of the technology company's stock worth $36,000 after acquiring an additional 1,238 shares during the last quarter. Bessemer Group Inc. raised its holdings in shares of Koninklijke Philips by 2,935.4% in the 1st quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company's stock worth $51,000 after acquiring an additional 1,908 shares during the last quarter. Castlekeep Investment Advisors LLC purchased a new position in Koninklijke Philips during the fourth quarter worth about $114,000. Allworth Financial LP boosted its holdings in Koninklijke Philips by 16.2% during the first quarter. Allworth Financial LP now owns 4,638 shares of the technology company's stock worth $115,000 after purchasing an additional 645 shares during the last quarter. Finally, Wealthquest Corp purchased a new position in Koninklijke Philips during the first quarter worth about $116,000. Institutional investors and hedge funds own 13.67% of the company's stock.

Koninklijke Philips Stock Up 0.9%

Koninklijke Philips stock traded up $0.24 during midday trading on Friday, hitting $27.47. 688,016 shares of the stock were exchanged, compared to its average volume of 1,237,589. Koninklijke Philips N.V. has a 52-week low of $21.48 and a 52-week high of $32.91. The stock has a market capitalization of $26.45 billion, a price-to-earnings ratio of 144.58, a price-to-earnings-growth ratio of 0.74 and a beta of 0.75. The business's 50-day moving average price is $24.79 and its 200-day moving average price is $25.00. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.69.

Koninklijke Philips (NYSE:PHG - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The technology company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.12. Koninklijke Philips had a net margin of 1.00% and a return on equity of 11.95%. The business had revenue of $5.05 billion for the quarter, compared to analysts' expectations of $4.35 billion. On average, research analysts expect that Koninklijke Philips N.V. will post 1.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of Koninklijke Philips from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy".

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.